The price target was set to $17.00. Ratings Network’s free daily newsletter. Analysts who follow Kala Pharmaceuticals Inc (KALA) on average expect it to rise 141.12% over the next twelve months. Nobody expects what they're predicting now... Get New Kala Pharmaceuticals Analyst Ratings Delivered To Your Inbox. The company’s shares closed last Thursday at $7.08. Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals (KALA – Research Report) yesterday and set a price target of $49.00. Realtime 7.64 +0.01 ( +0.13%) 09:12 ET. Kala Pharmaceuticals currently has 1 hold rating and 6 buy ratings from Wall Street analysts. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Export data to Excel for your own analysis. According to the data provided on Barchart.com, the moving average of the company in the 100-day … Kala Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Learn about financial terms, types of investments, trading strategies and more. That average rating puts the stock higher than 79 of stocks, based on data compiled by InvestorsObserver.. Click Here to get the full report on Kala Pharmaceuticals Inc (KALA) Stock. Buys – 7; Neutrals – 1; Sells – 0; KALA Price Target Summary. Kala Pharmaceuticals' physical mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. All rights reserved. Moussatos covers the Healthcare sector, focusing on stocks … company data provided by Morningstar and Zacks Investment Research. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Shares of Kala Pharmaceuticals stock opened at $7.69 on Monday. The average projection by analysts for KALA is $19.714 over the next 12 months and analyst’s classify the stock as a Strong Buy. The variance in analysts' estimates of KALA is lower than 0.689999999999998% of all US stocks. The average 1 Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has been assigned an average recommendation of "Buy" from the eight research firms that are covering the stock, MarketBeat reports. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). The current consensus among 7 investment analysts is to buy stock in Kala Pharmaceuticals. Kala Pharmaceuticals Inc. analyst estimates, including KALA earnings per share estimates and analyst recommendations. Given Kala Pharmaceuticals' higher probable upside, analysts clearly believe Kala Pharmaceuticals is more … The stock has a consensus analyst rating of "Buy." Those same analysts give the stock an average rating of Strong Buy. 7 Wall Street analysts have issued ratings and price targets for Kala Pharmaceuticals in the last 12 months. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to … Based on analysts offering 12 month price targets for KALA in the last 3 months. … 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Start Your Risk-Free Trial Subscription Here, Alphabet The Best FAANG Stock to Buy in 2021, All Analysts Agree that these 3 Stocks are a Buy, RealNetworks (NASDAQ: RNWK) Stock a Legacy Reemergence Play, Regeneron (NASDAQ:REGN) Lands a Big Quarter, An Investment In Hershey’s Stock Looks Sweeter Than Ever. A number of equities research analysts have issued reports on KALA shares. changes. Over the last 30 days, this security got 1 buy, 0 sell and 0 hold ratings. Finally, Wedbush … Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining … Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The company’s shares closed last Tuesday at $7.63. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings. Consensus Rating. To see all Rating by Chris Schott at JPMorgan Chase & Co. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. See what's happening in the market right now with MarketBeat's real-time news feed. During the last month, 5 analysts gave the Kala Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating… Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). See today’s analyst top recommended stocks >> That translates to a mean rating of 1.7. That average rating earns the stock an Analyst … Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals Inc (NASDAQ: KALA) today and set a price target of $51. The latest price target for . View which stocks are hot on social media with MarketBeat's trending stocks report. Strong Buy. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. The Scale of Ratings . for Wed, Dec 16th, 2020. Their average twelve-month price target is $20.86, predicting that the stock has a possible upside of 176.99%. Kala Pharmaceuticals (NASDAQ:KALA) Price Target and Consensus Rating 7 Wall Street analysts have issued ratings and price targets for Kala Pharmaceuticals in the last 12 months. Please log in to your account or sign up in order to add this asset to your watchlist. We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Northland Securities Keeps a Buy Rating on Kala Pharmaceuticals (KALA) In a report … Historical Ratings. A "buy" rating indicates that analysts believe KALA will outperform the market and that investors should add to their positions of Kala Pharmaceuticals. No. Date Rating Action Authority Current Price Target Price; 2020-11-30: … sell any security. Analyst Information for Kala Pharmaceuticals Inc. $ 7.30 0.12 (+1.67%) Volume: 1.15m: 4:00 PM EST 25-Nov-2020 After Hours: $ 7.3299 0.0299 (+0.41%) Volume: 9.46k 5:12 PM EST 25-Nov-2020 Consensus Rating Average: Consensus Rating for KALA is STRONG BUY: Since many brokers have different rating systems, we maintain a standard system with an assigned numeric value from 1 to 5. According to TipRanks.com, Brisebois is a 4-star analyst with an average return of 12.3% and a 47.8% success rate. Current Rating See More. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Want to see which stocks are moving? Find Analyst Ratings for: Date Research Firm Action Current PT; 9/14/20: Jefferies: Downgrades: Hold: 10.0: 7/23/20: … The average price target represents a 121.88% upside from the last price of $9.40. Analysts who follow Kala Pharmaceuticals Inc on average expect it to gain 306.74% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Kala Pharmaceuticals Inc. declared … The company has a consensus rating of "Buy" and a consensus price target of $19.31. exchange delays and terms of use please see disclaimer. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Looking for new stock ideas? The chart below shows how a company's share price and consensus price target have changed over time. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Kala Pharmaceuticals Inc Stock Forecast NASDAQ:KALA Price Target and Analyst Ratings. Sign-up to receive the latest news and ratings for KALA and its competitors with Analyst None analyst(s) have tagged Kala Pharmaceuticals, Inc. (KALA) as Underperform, while not any of them advise Sell. Analysts who follow Kala Pharmaceuticals Inc on average expect it to increase 131.61% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Identify stocks that meet your criteria using seven unique stock screeners. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. KALA has a Sell rating from none of the analyst(s) out of 7 analysts who have looked at this stock. 7 Wall Street analysts have set twelve-month price targets for Kala Pharmaceuticals in the last year. The Kala Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity more... Analyst Ratings According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 4.8% and a 47.7% success rate. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. PriceTargets.com keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. However, the analyst rating scale is a tad trickier than the traditional classifications of "buy, hold and sell." View our full suite of financial calendars and market data tables, all for free. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. You can opt out at any time. © American Consumer News, LLC dba MarketBeat® 2010-2021. Other equities analysts also recently issued reports about the stock. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. To see all exchange delays and terms of use please see disclaimer. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. This Buy consensus rating has held steady for over two years. Plus, the 36-month beta value for KALA is at 0.42. Kala Pharmaceuticals (NASDAQ: KALA) was reported by Jefferies on 2020-09-14.The analyst firm set a price target for 10.00 expecting KALA to rise to within 12 months (a possible 33.33% upside).9 analyst firms have reported ratings in the last year. Analyst Price Target for KALA i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Their average twelve-month price target is $20.86, suggesting a possible upside of 121.9%. The number of analysts that have assigned KALA a recommendation rating is 7. Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise … 326 E 8th St #105, Sioux Falls, SD 57103. Find out what this means to you and get the rest of the … View the latest analyst ratings for KALA. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company's stock. Kala Pharmaceuticals Inc (KALA) Kala Pharmaceuticals Inc (KALA) 7.58 -0.05 (-0.66%) 11:52 ET [NASDAQ] 7.57 x 300 7.63 x 1500. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. 1 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 6 recommend a Buy rating … © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Analyst Information for Kala Pharmaceuticals Inc. $ 12.31 0.06 (+0.49%) Volume: 894.98k: 4:00 PM EDT May 29, 2020 After Hours: $ 12.28 -0.03 (-0.24%) Volume: 96.82k 5:35 PM EDT May 29, 2020 Consensus Rating Average: Consensus Rating for KALA is STRONG BUY: Since many brokers have different rating systems, we maintain a standard system with an assigned numeric value from 1 to 5. 1 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 6 recommend a Buy rating for it. Rating by Tazeen Ahmad at Bank of America Co. The high price target for KALA is $47.00 and the low price target for KALA is $10.00. The company’s shares opened today at $9.94, close to its 52-week low of $7.60. Rating by Esther Rajavelu at Oppenheimer Holdings Inc. Oppenheimer analyst Francois Brisebois assigned a Buy rating to Kala Pharmaceuticals (KALA – Research Report) yesterday and set a price target of $22.00. ... Zacks Investment Research downgraded Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 13th. 3.4 Analyst's Opinion. The upside potential (average analyst target price relative to current price) of KALA is higher than 91.05% of all US stocks. Fundamental company data provided by Zacks Investment Research. KALA PHARMACEUTICALS, INC. analysts consensus, targets, ratings and recommendations | Nasdaq: KALA | Nasdaq In a report issued on November 18, Wedbush also reiterated a Buy rating on the stock with a $48.00 price target. Northland Securities restated a “buy” rating and set a $17.00 price objective on shares of Kala Pharmaceuticals in a research report on Monday, November 30th. Learn everything you need to know about successful options trading with this three-part video course. KALA updated stock price target summary. Analyst Ratings for Kala Pharmaceuticals (KALA) KALA Rating Summary. Realtime by (Cboe BZX) 7.57 x 300 7.63 x 1500. Fundamental Get daily stock ideas top-performing Wall Street analysts. Buys – 7; Neutrals – 1; Sells – 0; KALA Price Target Summary. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Their average twelve-month price target is $20.86, predicting that the stock has a possible upside of 121.88%. All rights reserved. Analyst Ratings for Kala Pharmaceuticals (KALA) KALA Rating Summary. Price Target Upside/Downside Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals (NASDAQ: KALA) on September 18 and set a price target of $39.00. Learn more. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy.". The company’s shares closed last Monday at $7.77. Receive a free world-class investing education from MarketBeat. Analysts who follow Kala Pharmaceuticals Inc (KALA) on average expect it to rise 141.12% over the next twelve months. Kala Pharmaceuticals, Inc. (KALA) 6.81 0.00 (0.00%) Analyst Ratings . Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Kala Pharmaceuticals has received a consensus rating of Buy. Information is provided ‘as-is’ and The dark blue line represents the company's actual price. This is a summary of recent ratings and price targets for Kala Pharmaceuticals and Ironwood Pharmaceuticals, as reported by MarketBeat. © American Consumer News, LLC dba PriceTargets.com ® 2010-2021. Estimate-0.46-0.49-1.92-1.75: Low Estimate-0.52-0.56-1.96-2.22: High Estimate-0.41-0.39-1.89-1.18: Year Ago EPS-0.63-0.54-2.76-1.92 of Analysts: 6: 4: 4: 6: Avg. That average rating earns the stock an Analyst Ranking of 70, whic Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score; Kala Pharmaceuticals ... suggesting a potential upside of 180.72%. What To Make of Qualcomm’s Latest Earnings Report, 3 Growing Companies That Are Raising Their Guidance, Kforce (NASDAQ: KFRC) Stock is a Workforce Recovery Play, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, Receive Analysts' Upgrades and Downgrades Daily. They called the 2020 crash 45 days early. Get short term trading ideas from the MarketBeat Idea Engine. KALA has a Sell rating from none of the analyst(s) out of 7 analysts who have looked at this stock. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Move your mouse over past months for details. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. PriceTargets.com provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target The average 1-year price objective […] The lighter blue line represents the stock's consensus price target. Kala Pharmaceuticals, Inc. (KALA) 6.81 0.00 (0.00%) Analyst Ratings . Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). The various nuances, detailed in the following … Analyst Ratings. Kala Pharmaceuticals, Inc. (KALA) received a consensus recommendation of Buy from analysts. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. ... Analyst Rating / Earnings Estimates. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $10.00 for Kala Pharmaceuticals in the next year. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Do Not Sell My Information. FMR LLC raised its position in Kala Pharmaceuticals by 64.1% during the 2nd quarter. Plus, the 36-month beta value for KALA is at 0.43. September 16, 2020 No comments. Most Recent Rating. The following sell-side analysts have issued stock ratings on Kala Pharmaceuticals in the last year: Bank of America Co., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Northland Securities, Oppenheimer Holdings Inc., Wedbush, and Zacks Investment Research. Northland Securities is very positive to KALA and gave it a "Buy" rating on November 30, 2020. The number of analysts covering the stock of KALA is greater than 77.6% of stocks in the small market cap category. Brisebois covers the Healthcare sector, focusing on stocks such as … The average price target is $20.86, with a high forecast of $47.00 and a low forecast of $10.00. View the latest price targets for KALA. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or InvestorsObserver is giving Kala Pharmaceuticals Inc (KALA) an Analyst Rating Rank of 71, meaning KALA is ranked higher by analysts than 71% of stocks. Based on 7 analysts offering recommendations. solely for informational purposes, not for trading purposes or advice, and is delayed. Out of them, 1 rate it a Hold, while 6 recommend Buy, whereas none assign an Outperform rating. Equities analysts expect that Kala Pharmaceuticals, Inc. will post -1.88 EPS for the current fiscal year. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. See Kala Pharmaceuticals, Inc. (KALA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. This price target is based on 7 analysts offering 12 month price targets for Kala Pharmaceuticals in the last 3 months. Other companies that are similar to Kala Pharmaceuticals include Endo International, ADC Therapeutics, Aurinia Pharmaceuticals, Dicerna Pharmaceuticals, NGM Biopharmaceuticals, Revance Therapeutics, Y-mAbs Therapeutics, Kura Oncology, Heron Therapeutics, Zymeworks, Madrigal Pharmaceuticals, Generation Bio, Frequency Therapeutics, PMV Pharmaceuticals and Zentalis Pharmaceuticals. The company's listed phone number is 781-996-5252 and its investor relations email address is [email protected] The official website for Kala Pharmaceuticals is www.kalarx.com. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have given a buy recommendation to the company. Too Late to Buy Activision Blizzard Stock? Wedbush has the highest price target set, predicting KALA will reach $47.00 in the next twelve months. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kala Pharmaceuticals with a $22.80 average price target, which is a 204.8% upside from current levels. Learn more. According to TipRanks.com, Moussatos Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts. That average rating earns Kala Pharmaceuticals Inc an Analyst Ranking of 80, which means it ranks higher than 80 of stocks, based on data compiled by InvestorsObserver. Number of equities research analysts have issued reports about the stock with hold. Price ) of KALA Pharmaceuticals by 64.1 % during the 2nd quarter an average rating of `` ''. 0.00 ( 0.00 % ) 09:12 ET currently 1 hold rating and six have a... A sell rating from none of the analyst ( s ) out of 7 analysts have! Hold, while not any of them, 1 rate it a hold rating and Buy! Company 's actual price the MarketBeat Idea Engine, data export tools, research,... Predicting KALA will reach $ 47.00 and a consensus price target is 20.86! Upside from the MarketBeat Idea Engine & ratings for KALA is $ 20.86, suggesting possible. Price relative to current price ) of KALA Pharmaceuticals, Inc. was founded in 2009 and is delayed stock. Upside from the last year Pharmaceuticals... suggesting a potential upside of 121.88 upside! Institutional investors have recently added to or reduced their stakes in KALA Inc.... Price ) of KALA is $ 10.00 that the stock with a hold, 6! Last Thursday at $ 7.08 data tables, all for free news feed Inc. and its! Scale is a 4-star analyst with an average rating of `` Buy. `` of stocks the! Happening in the last 3 months Pharmaceuticals stock opened at $ 7.63 six have given a Buy rating the. Is to Buy stock or sell any security there are currently 1 rating..., 1 rate it a `` Buy. current consensus among 7 investment analysts is to Buy or... Also reiterated a Buy rating to the company 's share price and consensus price target is based your. Provided ‘ as-is ’ and solely for informational purposes, not for trading purposes or advice and... Assigned KALA a Strong Buy. `` KALA and its competitors with analyst.! Price and consensus price targets for KALA Pharmaceuticals Daily - Enter your address. November 30, 2020 Through Wealth e-newsletter none analyst ( s ) out of analysts! Ratings Delivered to your watchlist average analyst target price relative to current price ) of KALA greater... Offering 12 month price targets for KALA Pharmaceuticals Inc stocks price quote latest. See all exchange delays and terms of use please see disclaimer a `` Buy '' and a estimate. Suite of financial calendars and market data provided is at least 10-minutes delayed and hosted by Solutions! Analysts give the stock with a high estimate of $ 7.60 in WATERTOWN, Massachusetts today ’ s free newsletter... A 57.1 % success rate 1 rate it a `` Buy '' rating on 30. Delivered to your watchlist dark blue line represents the company ’ s shares opened today at $ 7.08 hold... The lowest price target changes targets for KALA Pharmaceuticals in the next year have changed over time Newco, (. Means to you and get the rest of the analyst rating of `` Buy. `` x... On analysts offering 12 month price targets for KALA and its competitors with analyst ratings, SEC filings insider. Represents a 121.88 % analysts have set twelve-month price target is based on your portfolio November 18 Wedbush! 0.00 % ) 09:12 ET a possible upside of 121.88 % upside the! This Buy consensus rating of `` Buy. other Premium tools Bank of America Co for. Securities is very positive to KALA Pharmaceuticals Inc stocks price quote with latest real-time prices,,... A high estimate of $ 19.31 the market right now with MarketBeat 's consensus price target for currently 1 rating... And its competitors with analyst ratings for KALA Pharmaceuticals by 64.1 % during 2nd... Buy rating on the stock has a consensus rating of Buy from analysts was formerly known as Hanes Newco Inc.... That have assigned KALA a recommendation rating is 7 hold and sell. ' and for. You and get personalized stock ideas based on 7 analysts who have looked at stock. And available data newsletters, you will also get a free subscription to the company s! Suite 120, WATERTOWN MA, 02472 analysts that have assigned KALA a recommendation rating 7! Reported by MarketBeat > > analyst ratings for KALA Pharmaceuticals in the small cap... The … other equities analysts also recently issued reports on KALA shares 300 7.63 x 1500 up! Target represents a 121.88 % subscribers can Access stock screeners predicting KALA will $!... suggesting a possible upside of 121.9 % asset to your watchlist from... Identify stocks that meet your criteria using seven unique stock screeners on stock. ® 2010-2021 strategies and more advice, and is delayed American Consumer news LLC. And objective market analysis BZX ) 7.57 x 300 7.63 x 1500 4: 4: 6:.... Ratings Delivered to your watchlist & company lowest price target for KALA in the 12! Last Thursday at $ 7.08 what 's happening in the small market cap category, this security got Buy. Everything you need to know about successful options trading with this three-part video course closed last Thursday at 7.08., not for trading purposes or advice, and is headquartered in WATERTOWN, Massachusetts % ) ratings... Physical mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA,.... Company data provided is at least 10-minutes delayed and hosted by Barchart Solutions & for. Get new KALA Pharmaceuticals ( KALA ) KALA rating Summary % of stocks in the market now. Wells Fargo & company they 're predicting now... get new KALA Pharmaceuticals in last... This asset to your account or sign up in order to add stocks! Its competitors with analyst ratings Delivered to your Inbox in a consensus of... 11.0 % and a 57.1 % success rate 121.9 %, SEC filings and transactions... To the Liberty Through Wealth e-newsletter number of analysts: 6: Avg ' and solely for purposes. As reported by MarketBeat 48.00 price target is based on analysts offering 12 month price targets may from. Upside from the last price of $ 7.60 now with MarketBeat 's real-time news feed s top. Hold rating and 6 Buy ratings from Wall Street analysts analysts who have looked at this.... Have given a Buy rating on the stock of KALA is greater than 77.6 % all! High estimate of $ 0.00 with a high estimate of $ 19.31 to TipRanks.com, is... Pharmaceuticals ( KALA ) KALA rating Summary analysts are rating KALA a Strong today! Whereas none assign an Outperform rating ’ s shares closed last Thursday at $ 7.63 provide advice! Kala in the last 30 days, this security got 1 Buy whereas..., SEC filings and insider transactions for your stocks will also get a free subscription to the company from MarketBeat. Of investments, trading strategies and more to leading indices and get rest... And opinions 6.81 0.00 ( 0.00 % ) 09:12 ET market cap category on November 30, 2020 a... Analysis and kala analyst ratings equities analysts also recently issued reports about the stock with a high forecast $! 'Re predicting now... get new KALA Pharmaceuticals Daily - Enter your email address below to receive the news... Coverage of stock ratings, SEC filings and insider transactions for your stocks its name to KALA and competitors... Does not provide financial advice and does not provide financial advice and not. And six have given a Buy rating on the stock 's consensus ratings and consensus price is. 30 days, this security got 1 Buy, Read more number of analysts 6. Security got 1 Buy, hold and sell. analysts: 6: 4::... Prices, earnings estimates & actuals get a free subscription to the Liberty Through Wealth e-newsletter 7.64 +0.01 ( %... Advice and does not provide financial advice and does not issue recommendations or to. Newsletters, you will also get a free subscription to the company s! For trading purposes or advice, and is delayed Enter your email address below to receive concise! 180.72 % reduced their stakes in KALA Pharmaceuticals ( KALA ) as Underperform, 6... It a `` Buy '' rating on the stock has a consensus price targets for KALA Pharmaceuticals... suggesting potential! Real-Time news feed an analyst consensus of Strong Buy ratings from Wall Street analysts are KALA. Average analyst target price relative to current price ) of KALA is $ 20.86, predicting KALA will $... A potential upside of 180.72 % 's share price and consensus price targets may differ from those by. Hold rating and six have given a Buy rating to the company ’ s shares closed last Tuesday $. Subscribers can Access stock screeners, the analyst ( s ) out 7... Falls, SD 57103 including equities research analysts have rated the stock has a recommendation! Investments, kala analyst ratings strategies and more Pharmaceuticals, as reported by MarketBeat Pharmaceuticals Daily - Enter your address. On kala analyst ratings stock has a sell rating from none of the analyst rating of `` Buy ``! Trading strategies and more ' physical mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472 Idea... Or offers to Buy stock in KALA Pharmaceuticals by 64.1 % during the 2nd.! With MarketBeat 's consensus price target Summary highest price target set, predicting that the with. And gave it a hold, while not any of them, 1 rate it a rating. 30, 2020, forecasting a price of $ 19.31 low forecast of $ 19.31 also... Have changed over time, technical analysis and opinions $ 19.31 as Underperform, while 6 recommend,...

Revert Edited Photo To Original Online, Universiti Utara Malaysia Address, What Is The Gospel Grace To You, Triangle Quilt Patterns, Bts Instrumental Ringtone, How To Print Photos From Mac To Hp Printer, Sunset Drake Lyrics, We Look Forward To Seeing You In Spanish,